Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Efficacy and safety of guselkumab and adalimumab for pustulotic arthro-osteitis and their impact on peripheral blood immunophenotypes

Fig. 1

Comparison of 6 months of treatment response between the guselkumab group (n = 12) and adalimumab group (n = 13). A Rate of DAPSA-LDA responders (%). B Rate of DAPSA-REM responders. C Rate of PPPASI-50 responders (%). D Rate of PPPASI-75 responders. E Rate of PPPASI-90 responders (%). *p<0.05, by Fisher’s exact test. Abbreviations: PPPASI Palmoplantar Pustulosis Area Severity Index, DAPSA disease activity in psoriatic arthritis, LDA low disease activity, REM remission

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us